NGS Streamlines Clonal Detection in Plasma Cells
November 15, 2025
-
2 min
Next-generation sequencing (NGS) offers a promising approach for early detection of monoclonal gammopathy of unknown significance (MGUS) and smoldering multiple myeloma (SMM) patients at high risk for AL amyloidosis. Data from Columbia University and Tufts University indicate NGS can accurately identify clonal immunoglobulin lambda sequences without requiring CD138 selection, showcasing its sensitivity and reliability. This method could facilitate timely interventions, crucial in preventing progression to systemic amyloidosis, thereby enhancing patient management in hematology and oncology.
1. NGS improves early detection of MGUS and SMM. 2. Eliminates need for CD138 selection. 3. 96.1% sensitivity in identifying clonal populations. 4. Study conducted by Columbia University and Tufts University. 5. Highlights importance of early detection for preventing AL amyloidosis. 6. High concordance (91.3%) with traditional Sanger sequencing. 7. Streamlines sample processing in clinical labs. 8. Potential impact on patient management in hematology.
Listen Tab content
